Similarly, glucagon-like peptide-1 (GLP-1) receptor agonists and multi-target incretins, such as semaglutide and tirzepatide, have demonstrated potent effects in MASLD by inducing weight loss and improving systemic metabolic health, thereby reducing the “fuel” for hepatic inflammation and steatosis [20,25,33,34]. The gene discussed is GLP1R; the disease is steatosis.